Literature DB >> 820641

Effect of cyclophosphamide on the immune response to Pseudomonas aeruginosa in mice.

C L Pierson, A G Johnson, I Feller.   

Abstract

Natural resistance in mice to Pseudomonas aeruginosa was decreased 10-fold with a single dose of 300 mg of cyclophosphamide (CY) per kg intraperitoneally. Mice were resistant to infection when immunized actively with Pseudomonas vaccine or passively with Pseudomonas immune serum before receiving CY. Syngeneic spleen, thymus and/or bone marrow cells were transfused into CY-treated recipient mice. Protective anti-Pseudomonas antibody was elicited in the recipient mice when they were vaccinated 1 day after receiving normal spleen cells and challenged 8 days after vaccination. When 1.6 X 10(7) normal thymus and bone marrow cells were infused before vaccination, 69% of the recipients of both cell preparations responded serologically compared with 15 and 27% of those receiving either thymus or bone marrow cells, respectively. CY-treated thymus or bone marrow cell recipients were resistant to Pseudomonas infection when 6 X 10(7) of either cell population was transfused.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 820641      PMCID: PMC420860          DOI: 10.1128/iai.14.1.168-177.1976

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  35 in total

1.  Destruction and regeneration of lymphocyte populations in the mouse spleen after cyclophosphamide treatment.

Authors:  F Dumont
Journal:  Int Arch Allergy Appl Immunol       Date:  1974

2.  Effect of lymphocytotherapy on the course of experimental Pseudomonas sepsis.

Authors:  A M Munster; A G Leary; S S Spicer; M W Fisher
Journal:  Ann Surg       Date:  1974-04       Impact factor: 12.969

3.  Normal granulocyte transfusion therapy: treatment of septicemia due to gram-negative bacteria.

Authors:  R G Graw; G Herzig; S Perry; E S Henderson
Journal:  N Engl J Med       Date:  1972-08-24       Impact factor: 91.245

4.  Clinical and pathologic characteristics of graft-versus-host disease produced in cyclophosphamide-treated adult mice.

Authors:  J S Sandberg; A H Owens; G W Santos
Journal:  J Natl Cancer Inst       Date:  1971-01       Impact factor: 13.506

5.  Infections caused by Pseudomonas species in patients with burns and in other surgical patients.

Authors:  B A Pruitt
Journal:  J Infect Dis       Date:  1974-11       Impact factor: 5.226

6.  Transplantation of bursal stem cells into cyclophosphamide-treated chicks. Redevelopment of bursal follicles.

Authors:  T Sorvari; A Toivanen; P Toivanen
Journal:  Transplantation       Date:  1974-06       Impact factor: 4.939

7.  Pseudomonas aeruginosa vaccine in cancer patients.

Authors:  L S Young; R D Meyer; D Armstrong
Journal:  Ann Intern Med       Date:  1973-10       Impact factor: 25.391

8.  Bacteremia due to Pseudomonas aeruginosa complicating neoplastic disease: a progress report.

Authors:  M L Tapper; D Armstrong
Journal:  J Infect Dis       Date:  1974-11       Impact factor: 5.226

9.  Granulocyte transfusion therapy of experimental Pseudomonas pneumonia.

Authors:  D C Dale; H Y Reynolds; J E Pennington; R J Elin; T W Pitts; R G Graw
Journal:  J Clin Invest       Date:  1974-09       Impact factor: 14.808

10.  Effect of vincristine sulfate on Pseudomonas infections in monkeys.

Authors:  S Saslaw; H N Carlisle; M Moheimani
Journal:  Infect Immun       Date:  1972-08       Impact factor: 3.441

View more
  8 in total

1.  Modulation of delayed-type hypersensitivity and cellular immunity to microbial vaccines: effects of cyclophosphamide on the immune response to tularemia vaccine.

Authors:  M S Ascher; D Parker; J L Turk
Journal:  Infect Immun       Date:  1977-11       Impact factor: 3.441

2.  Relationship between gentamicin susceptiblity criteria and therapeutic serum levels for Pseudomonas aeruginosa in mouse infection model.

Authors:  T I Nicas; L E Bryan
Journal:  Antimicrob Agents Chemother       Date:  1978-05       Impact factor: 5.191

3.  Therapeutic effect of granulocyte colony-stimulating factor and cephem antibiotics against experimental infections in neutropenic mice induced by cyclophosphamide.

Authors:  H Wakiyama; S Tsuru; N Hata; M Shinomiya; N Shinomiya; M Noritake; Y Umezawa; M Rokutanda
Journal:  Clin Exp Immunol       Date:  1993-05       Impact factor: 4.330

4.  Mechanisms of protective immunogenicity of microbial vaccines: effects of cyclophosphamide pretreatment in Venezuelan encephalitis, Q fever and tularaemia.

Authors:  M S Ascher; P B Jahrling; D G Harrington; R A Kishimoto; V G McGann
Journal:  Clin Exp Immunol       Date:  1980-08       Impact factor: 4.330

5.  Effect of calcium chloride on experimental infection of mice with Pseudomonas aeruginosa.

Authors:  Y Tamura; S Tanaka
Journal:  Infect Immun       Date:  1985-06       Impact factor: 3.441

6.  Cell-mediated immunity and delayed-type hypersensitivity in Pseudomonas aeruginosa-infected mice.

Authors:  M Campa; L Toca; S Lombardi; C Garzelli; V Colizzi; G Falcone
Journal:  Med Microbiol Immunol       Date:  1982       Impact factor: 3.402

7.  Studies of lung infections caused by Pseudomonas aeruginosa in mice treated with cyclophosphamide.

Authors:  P Mayer; H Walzl
Journal:  Infection       Date:  1983 Mar-Apr       Impact factor: 3.553

8.  Reduced resistance to Pseudomonas septicaemia in diabetic mice.

Authors:  Y Kitahara; T Ishibashi; Y Harada; M Takamoto; K Tanaka
Journal:  Clin Exp Immunol       Date:  1981-03       Impact factor: 4.330

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.